We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Trubion Pharmaceuticals (MM) | NASDAQ:TRBN | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.60 | 0 | 01:00:00 |
FORM 3
|
Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Expires: January 31, 2008 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person * Mohler Kendall |
2. Date of Event Requiring Statement (MM/DD/YYYY)
|
3. Issuer Name and Ticker or Trading Symbol Trubion Pharmaceuticals, Inc [TRBN] |
|
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director
_____ 10% Owner
___ X ___ Officer (give title below) _____ Other (specify below) SVP Research and Development / |
|
|
5. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_
X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned |
|||
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock | 140206 | D |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative Security |
5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (right to buy) | (1) | 12/20/2012 | Common Stock | 34882 | $0.314 | D | |
Stock Option (right to buy) | (2) | 12/16/2014 | Common Stock | 39730 | $0.314 | D | |
Stock Option (right to buy) | (2) | 2/3/2015 | Common Stock | 13243 | $0.314 | D | |
Stock Option (right to buy) | (2) | 11/30/2015 | Common Stock | 19865 | $2.697 | D | |
Stock Option (right to buy) | (3) | 1/25/2016 | Common Stock | 7335 | $6.522 | D | |
Stock Option (right to buy) | (2) | 3/8/2016 | Common Stock | 19865 | $6.522 | D | |
Stock Option (right to buy) | (4) | 2/24/2016 | Common Stock | 23919 | $6.522 | D | |
Stock Option (right to buy) | (5) | 4/28/2015 | Common Stock | 770 | $0.314 | D | |
Stock Option (right to buy) | (6) | 1/31/2018 | Common Stock | 52000 | $8.98 | D |
Explanation of Responses: | |
( 1) | Fully vested as of November 15, 2006. |
( 2) | Vests at the rate of 25% on July 13, 2005, and 1/48th monthly thereafter, such that all of the shares will be fully vested as of July 13, 2008. |
( 3) | Fully vested as of January 1, 2007. |
( 4) | Vests at the rate of 25% on January 1, 2007, and 1/48th of monthly thereafter, such that all of the shares will be fully vested as of January 1, 2010. |
( 5) | Fully vested as of January 1, 2006. |
( 6) | Vests at the rate of 1/48th on February 1, 2008, and 1/48th monthly thereafter, such that all of the shares will be fully vested as of January 1, 2012. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
Mohler Kendall
2401 4TH AVE., SUITE 1050 SEATTLE, WA 98121 |
|
|
SVP Research and Development |
|
Signatures
|
||
/s/ Kathleen Deeley, Attorney-in-fact | 3/24/2008 | |
** Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Trubion Pharmaceuticals (MM) Chart |
1 Month Trubion Pharmaceuticals (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions